Whole-Genome Sequences of Five *Burkholderia pseudomallei* Isolates from Australian Cystic Fibrosis Patients

Linda T. Viberg, Erin P. Price, Timothy J. Kidd, Scott C. Bell, Bart J. Currie, Derek S. Sarovich

Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia; Queensland Children’s Medical Research Institute, The University of Queensland, Herston, Queensland, Australia; Center for Infection and Immunity, Queen’s University Belfast, Northern Ireland; Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia; Department of Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia

We report here five improved high-quality draft genomes of *Burkholderia pseudomallei* isolated from Australian cystic fibrosis (CF) patients. This pathogen is rarely seen in CF patients. These genomes will be used to better understand chronic carriage of *B. pseudomallei* in the CF lung and the within-host evolution of longitudinal isolates from these patients.

*B. pseudomallei* is the causative agent of melioidosis, a potentially lethal disease with multiple clinical presentations, of which pneumonia is most common (1–3). Infection with *B. pseudomallei* is acquired following accidental percutaneous inoculation with contaminated soil or water, or by inhalation or ingestion. Most reported cases of melioidosis are from the regions of northern Australia and Southeast Asia that are highly endemic for *B. pseudomallei*, with sporadic reports from other endemic regions, including the Middle East, Africa, South and Central America, and the Caribbean (4, 5).

Cystic fibrosis (CF) patients typically develop infections caused by a range of opportunistic pathogens, such as *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Haemophilus influenzae*, which may be eradicated in the early phases, but with increasing age, these can develop into a chronic infection (6). The factors that promote the development of infection are complex but include the abnormal composition of the airway lining fluid as a consequence of abnormal expression of the CF transmembrane regulator protein (CFTR). *B. pseudomallei* has been identified in the CF lung in a small proportion of CF patients living or traveling to regions endemic for the pathogen (7–12).

*B. pseudomallei* is known to cause chronic infections that can be difficult to treat and, in certain instances, persist for years (13, 14). Although many conventional CF-associated pathogens have been studied in detail, little is known about how *B. pseudomallei* behaves within the CF lung. Reports have demonstrated that, like most *B. pseudomallei* infections, clinical symptoms can present as either acute or chronic disease (9). Here, we present improved high-quality draft genome sequences (15) of the initial *B. pseudomallei* strains isolated from five Australian CF patients with chronic *B. pseudomallei* infection.

DNA was extracted from purified culture, as previously reported (16). The DNA samples were subjected to whole-genome sequencing (WGS) from a paired-end Nextera library and with a ~300-bp insertion size using the Illumina HiSeq 2000 platform (Illumina, Inc., San Diego, CA) at Macrogen, Inc. (Geumcheon-gu, Seoul, Republic of Korea). The genomes of the isolates (excluding MSHR8441) were also sequenced using the 454 Genome Sequencer FLX+ instrument (454 Life Sciences, Branford, CT, USA). The sequence reads were quality-filtered and subsequently assembled via hybrid assembly using MIRA (17), followed by PAGIT (18), SSPACE version 2.0 (19), and GapFiller version 1.10 (20) polishing. MSHR8441 was assembled using Velvet version 1.2.10 (21) instead of MIRA but included the same quality improvement steps listed above. The contigs were reordered against *B. pseudomallei* MSHR1153 (GenBank accession numbers CP009271 and CP009272 [22]) or K96243 (GenBank accession numbers NC_006350 and NC_006351 [23]) using Mauve (24). The contig joins were manually checked for syntenic among reference genomes using BLAST and were stitched, if possible. A summary of the final genome assembly statistics is provided in Table 1.

These genomes will provide useful reference strains for use in

### Table 1: Statistics for the 5 *Burkholderia pseudomallei* draft genome sequences

| Strain       | Alternate ID | Accession no. | Genome size (bp) | No. of contigs | N\(_{\text{50}}\) (bp) | G+C content (%) |
|--------------|-------------|---------------|------------------|----------------|-------------------------|-----------------|
| QCMRI_BP07   | MSHR5651    | JYBG000000000 | 7,767,989         | 139            | 227,078                 | 67.6            |
| QCMRI_BP13   | MSHR8436    | JYBH000000000 | 7,356,204         | 98             | 241,256                 | 68.0            |
| QCMRI_BP18   | MSHR5662    | JYBI000000000 | 7,391,892         | 83             | 755,997                 | 68.0            |
| QCMRI_BP28   | MSHR8438    | JYBI000000000 | 7,565,815         | 161            | 398,485                 | 67.7            |
| QCMRI_BP32   | MSHR8441    | JYBK000000000 | 7,108,439         | 39             | 371,315                 | 68.2            |
analyses of longitudinal isolates from the same patient and provide novel insights into the within-host evolution and adaptation of *B. pseudomallei* in the CF lung. More broadly, these genomes will be useful for identifying parallel evolutionary mechanisms with other Gram-negative pathogens affecting the CF lung.

**Nucleotide sequence accession numbers.** The genome accession numbers for the assemblies deposited in DDBJ/ENA/GenBank are listed in Table 1.

**ACKNOWLEDGMENTS**

We thank Mark Mayo and Vanessa Theobald for laboratory assistance, Roche Diagnostics Australia Pty Ltd, for kindly providing the 454 sequence data used in our study, and the Rebecca L. Cooper Medical Research Council via award 1046812.

**REFERENCES**

1. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18:383–416. http://dx.doi.org/10.1128/CMR.18.2.383-416.2005.

2. Currie BJ, Ward L, Cheng AC. 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 4:e4900. http://dx.doi.org/10.1371/journal.pntd.0000900.

3. Meumann EM, Cheng AC, Ward L, Currie BJ. 2012. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin Infect Dis 54:362–369. http://dx.doi.org/10.1093/cid/cir808.

4. Wiersinga WJ, Currie BJ, Peacock SJ. 2012. Melioidosis. N Engl J Med 367:1035–1044. http://dx.doi.org/10.1056/NEJMra1204699.

5. Dance DA. 2015. Melioidosis in Puerto Rico: the iceberg slowly emerges. Clin Infect Dis 60:251–253. http://dx.doi.org/10.1093/cid/ciu768.

6. O’Sullivan BP, Freedman SD. 2009. Cystic fibrosis. Lancet 373:1891–1904. http://dx.doi.org/10.1016/S0140-6736(09)60327-5.

7. Currie BJ. 2003. Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions. Eur Respir J 22:542–550. http://dx.doi.org/10.1183/09031936.03.0006203.

8. O’Carroll MR, Kidd TJ, Coulter C, Smith HV, Rose BR, Harbour C, Bell SC. 2003. *Burkholderia pseudomallei*: another emerging pathogen in cystic fibrosis. Thorax 58:1087–1091. http://dx.doi.org/10.1136/thorax.58.12.1087.

9. Barth AL, de Abreu e Silva FA, Hoffmann A, Vieira MI, Zavascki AP, Bell SC. 2007. Cystic fibrosis patient with *Burkholderia pseudomallei* infection acquired in Brazil. J Clin Microbiol 45:4077–4080. http://dx.doi.org/10.1128/JCM.01386-07.

10. Corral DM, Coates AL, Yau YC, Tellier R, Glass M, Jones SM, Waters VJ. 2008. *Burkholderia pseudomallei* infection in a cystic fibrosis patient from the Caribbean: a case report. Can Respir J 15:237–239.

11. O’Sullivan BP, Torres B, Conidi G, Smole S, Gauthier C, Stauffer KE, Glass MB, Gee JE, Blaney D, Smith TL. 2011. *Burkholderia pseudomallei* infection in a child with cystic fibrosis: acquisition in the western hemisphere. Chest 140:239–242. http://dx.doi.org/10.1378/chest.10-3336.

12. Radhakrishna N, Morton J. 2015. *Burkholderia pseudomallei* in cystic fibrosis and treatment complications. Respirol Case Rep. 3:1–2. http://dx.doi.org/10.1002/rcr2.86.

13. Price EP, Sarovich DS, Mayo M, Talsky A, Drees KP, Kaestli M, Beckstrom-Sternberg SM, Babić-Sternberg J, Kidä TJ, Bell SC, Keim P, Pearson T, Currie BJ. 2013. Within-host evolution of *Burkholderia pseudomallei* over a twelve-year chronic carriage infection. mBio 4(4):e00388-13. http://dx.doi.org/10.1128/mBio.00388-13.

14. Price EP, Sarovich DS, Viberg L, Mayo M, Kaestli M, Talsky A, Foster JT, Keim P, Pearson T, Currie BJ. 2015. Whole-genome sequencing of *Burkholderia pseudomallei* isolates from an unusual melioidosis case identifies a polyclonal infection with the same multilocus sequence type. J Clin Microbiol 53:282–286. http://dx.doi.org/10.1128/JCM.02560-14.

15. Chain PS, Grahan DM, Fulton RS, Fitzgerald MG, Hostetler J, Muzny D, Ali J, Birren B, Bruce DC, Buahay C, Cole JR, Ding Y, Dungan S, Field D, Garrity GM, Gibbs R, Graves T, Han CS, Harrison SH, Highlander S, Hugenholtz P, Hongrae K, Koren S, Knapik LJ, Kubelka M, Laplante B, Lapidus A, Moffatt SA, Markowitz V, Metha T, Nelson KE, Parkhill J, Pflucker S, Qin X, Read TD, Schmutz J, Sozhamannan S, Stankert PE, Strausberg RL, Sutton G, Thomson NR, Tiedje JM, Weinstock GM, Wollam A, Dettter JC. 2009. Genomics. Genome project standards in a new era of sequencing. Science 326:236–237. http://dx.doi.org/10.1126/science.1180614.

16. Currie BJ, Gal D, Mayo M, Ward L, Godoy D, Spratt BG, Lipuma PJ. 2007. Using BOX-PCR to exlude a clonal outbreak of melioidosis. BMC Infect Dis 7:68. http://dx.doi.org/10.1186/1471-2334-7-68.

17. Chevreux B, Pfisterer T, Drescher B, Driesel AJ, Müller WE, Wetter T, Suhai S. 2004. Using the mireAST assembler for reliable and automated mRNA transcript assembly and SNP detection in sequenced ESTs. Genome Res 14:1147–1159. http://dx.doi.org/10.1101/gr.191740.

18. Swain MT, Tsai IJ, Assela SA, Newbold C, Berriman M, Otto TD. 2012. A post-assembly genome-improvement toolkit (PAGIT) to obtain annotated genomes from contigs. Nat Proto 7:1260–1268. http://dx.doi.org/10.1038/nprot.2012.068.

19. Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W. 2011. Scaffolding pre-assembled contigs using SPSPACE. Bioinformatics 27:578–579. http://dx.doi.org/10.1093/bioinformatics/btp683.

20. Boetzer M, Pirovano W. 2012. Toward almost closed genomes with GapFiller. Genome Biol 13:R36. http://dx.doi.org/10.1186/gb-2012-13-6-r36.

21. Zerbino DR, Birney E. 2008. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 18:821–829. http://dx.doi.org/10.1101/gr.074492.107.

22. Johnson SL, Baker AL, Chain PS, Currie BJ, Daligault HE, Davenport KW, Davis CB, Inglis TJ, Kaestli M, Koren S, Mayo M, Merritt AJ, Price EP, Sarovich DS, Warner J, Rosovitz MJ. 2015. Whole-genome sequences of 80 environmental and clinical isolates of *Burkholderia pseudomallei*. Genome Announc 3(1):e01284-14. http://dx.doi.org/10.1128/genomeA.01284-14.

23. Holden MT, Titball RW, Peacock SJ, Cerdeño-Tárraga AM, Atkins T, Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, Sebaihia M, Thomson NR, Bason N, Beacham IR, Brooks K, Brown KA, Brown NF, Challis GL, Cherevach I, Chillingworth T. 2004. Genomic plasticity of the causative agent of melioidosis, *Burkholderia pseudomallei*. Proc Natl Acad Sci U S A 101:14240–14245. http://dx.doi.org/10.1073/pnas.0403320101.

24. Rissman AJ, Mau B, Biehl BS, Darling AE, Gasner JD, Perna NT. 2009. Reordering contigs of draft genomes using the mauve aligner. Bioinformatics 25:2071–2073. http://dx.doi.org/10.1093/bioinformatics/btp356.